argenx stock holds near USD 988 as biotech outlook sharpens

Published on 09/23/2026 at 11:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

argenx stock closed at USD 988.20 on September 23, 2026, 7.9 percent below its 52-week high. Vyvgart sales topped USD 1 billion in its second year.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

argenx stock (ISIN NL0010832176) closed at USD 988.20 on Nasdaq on September 23, 2026, down 0.21 percent from the previous close. The price stood 7.9 percent below the 52-week high of USD 1,072.75 and above the 52-week low of USD 661.85, putting the market value at USD 61.454 billion.

Nasdaq price stays below yearly high

Yahoo Finance reported a trading range of USD 986.56 to USD 1,001.95 for September 23, 2026, with volume of 231,642 shares. The stock's position between the daily low and high shows a contained session rather than a decisive break of either level.

The market is assigning a substantial valuation to the company's commercial platform. The current market capitalization of USD 61.454 billion is supported by the scale of Vyvgart, but it also leaves the share price sensitive to clinical execution and sales growth.

Vyvgart clears billion dollar mark

As MSN reported on September 23, 2026, Vyvgart generated more than USD 1 billion in annual sales in its second year on the market. That commercial milestone gives the company a measurable base while investors wait for additional products and indications to contribute.

The same report described empasiprubart as a potential long-term growth driver, with peak global annual revenue projected at USD 6.6 billion in 2036. The comparison between more than USD 1 billion in current annual Vyvgart sales and the USD 6.6 billion long-term projection highlights both the opportunity and the time required to reach it.

Clinical risk remains material

The growth case still depends on clinical outcomes. MSN reported on September 23, 2026 that a crucial empasiprubart trial readout is expected in the fourth quarter and that Morgan Stanley assigned the drug a 50 percent probability of success.

Analyst expectations also remain above the quoted price. Yahoo Finance listed an average target of USD 1,180.61, compared with the September 23, 2026 close of USD 988.20, a difference of USD 192.41 or 19.5 percent. The same page showed a low target of USD 900 and a high target of USD 1,450, underscoring the wide range of outcomes embedded in current estimates.

Stock closes at USD 988.20

argenx stock closed at USD 988.20 on Nasdaq on September 23, 2026, with a daily change of minus 0.21 percent. Its 52-week range was USD 661.85 to USD 1,072.75, while market capitalization stood at USD 61.454 billion.